Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
02/20/2017 02/21/2017 02/22/2017 02/23/2017 02/24/2017 Date
50.35(c) 52.78(c) 52.3(c) 52.95(c) 51.9(c) Last
67 391 226 033 240 454 151 483 179 509 Volume
+1.66% +4.83% -0.91% +1.24% -1.98% Change
More quotes
Financials (€)
Sales 2016 50,1 M
EBIT 2016 -59,4 M
Net income 2016 -48,7 M
Finance 2016 276 M
Yield 2016 -
Sales 2017 51,4 M
EBIT 2017 -48,0 M
Net income 2017 -38,7 M
Finance 2017 244 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 24,7x
EV / Sales2017 24,7x
Capitalization 1 513 M
More Financials
Company
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics and research applications.It operates through the following segments: Partnered Discovery, Proprietary Development and AbD Serotec.The Partnered Discovery segment involves technologies for the generation of human... 
More about the company
Surperformance© ratings of MorphoSys AG
Trading Rating : Investor Rating :
More Ratings
Latest news on MORPHOSYS AG
02/21 MORPHOSYS AG : MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Cl..
02/21 MORPHOSYS : Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study wi..
02/21 DGAP-NEWS : MorphoSys-Tochter Lanthio Pharma startet klinische Entwicklung mit d..
02/21 DGAP-NEWS : MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clini..
02/15 MORPHOSYS AG : District Court Grants MorphoSys's Request to Add Second Patent in..
02/15 MORPHOSYS : District Court Grants MorphoSys's Request to Add Second Patent in La..
02/15 DGAP-NEWS : District Court Grants MorphoSys's Request to Add Second Patent in La..
02/15 DGAP-NEWS : US-Gericht billigt Antrag von MorphoSys, in das Patentverfahren gege..
02/13 MORPHOSYS : to Present at Upcoming Conference
02/10 MORPHOSYS AG : MorphoSys to Present at Upcoming Conference
More news
Sector news : Biotechnology & Medical Research - NEC
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
02/21MorphoSys's Subsidiary Lanthio #Pharma Initiates First-in-Human Clinical Stud.. 
02/21MorphoSys : Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study.. 
01/12MorphoSys AG Partner To Start Phase 2 Trial With Bimagrumab In Obese Patients.. 
01/05Dr. To Become New Chief Development Officer Of MorphoSys AG  
01/05MorphoSys : Dr. Malte Peters to Become New Chief Development Officer of Morph.. 
More tweets
Qtime:21
News from SeekingAlpha
01/12 Novartis to launch mid-stage study of bimagrumab in obese type 2 diabetics
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
2016 Morphosys Ag (MPSYY) Investor Presentation - Slideshow
2016 MorphoSys' (MPSYF) CEO Simon Moroney on Q3 2016 Results - Earnings Call Trans..
2016 MorphoSys AG reports 9M results
Advertisement
Chart MORPHOSYS AG
Duration : Period :
MorphoSys AG Technical Analysis Chart | MOR | DE0006632003 | 4-Traders
Full-screen chart
Technical analysis trends MORPHOSYS AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 63,1 €
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Simon E. Moroney Chief Executive Officer
Gerald Heinz Möller Chairman-Supervisory Board
Jens Holstein Chief Financial Officer
Marlies Sproll Chief Scientific Officer
Steffen Pohlenz Head-Information Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MORPHOSYS AG6.46%1 597
INCYTE CORPORATION21.62%24 852
QUINTILES IMS HOLDINGS..2.72%18 301
CELLTRION, INC.--.--%10 911
LONZA GROUP AG2.67%10 319
SEATTLE GENETICS, INC.19.52%8 939
More Results